Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by significant use of paracetamol as API in large number of OTC drugs, wide application of paracetamol as first-line therapy for symptomatic relief, and rising prevalence of chronic conditions and prescription drug use.
The paracetamol market is segmented as below:
By Application
- Surgical
- Non-surgical
By Formulation
- Powder
- Granules
By Geography
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the paracetamol market covers the following areas:
- Paracetamol market sizing
- Paracetamol market forecast
- Paracetamol market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
Executive Summary
The following companies are recognized as the key players in the global paracetamol market: Anhui Fubore Pharmaceutical And Chemical Co. Ltd., Anqiu Luan Pharmaceutical Co. Ltd., ATABAY KIMYA SANAYI TICARET AS, Biological E. Ltd., Cipla Inc., GlaxoSmithKline Plc, Granules India Ltd., Mallinckrodt Plc, Sanofi SA, SEQENS GROUP, Sri Krishna Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Trugen Pharmaceuticals Pvt Ltd., Zhejiang Kangle Pharmaceutical Co. Ltd., and Zhengzhou Sino Chemical Co. Ltd..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is rising preference for extended release formulations."
According to the report, one of the major drivers for this market is the significant use of paracetamol as API in large number of OTC drugs.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Anhui Fubore Pharmaceutical And Chemical Co. Ltd.
- Anqiu Luan Pharmaceutical Co. Ltd.
- ATABAY KIMYA SANAYI TICARET AS
- Biological E. Ltd.
- Cipla Inc.
- GlaxoSmithKline Plc
- Granules India Ltd.
- Mallinckrodt Plc
- Sanofi SA
- SEQENS GROUP
- Sri Krishna Pharmaceuticals Ltd.
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- Trugen Pharmaceuticals Pvt Ltd.
- Zhejiang Kangle Pharmaceutical Co. Ltd.
- Zhengzhou Sino Chemical Co. Ltd.